CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc., which trades under the ticker PBAX on Nasdaq, is the operating company that resulted from the de-SPAC business combination between Phoenix Biotech Acquisition Corp and CERO Therapeutics, Inc. Phoenix Biotech Acquisition Corp completed its initial public offering in 2021, sponsored by Phoenix Biotech Sponsor, LLC, with a focus on the biotechnology and life sciences sector. The company is now a clinical-stage biopharmaceutical firm developing chimeric engulfment receptor T-cell, or CER-T, therapies targeting solid tumor cancers. The November 2024 Form 8-K filing reflects the company's ongoing public reporting obligations following the completion of its business combination. Sign up for a SpacDesk account to access the full filing history, deal timeline, and sponsor data for PBAX and hundreds of other SPAC transactions.